Middle East Respiratory Syndrome (MERS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

Middle East Respiratory Syndrome (MERS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

  • October 2019 •
  • 70 pages •
  • Report ID: 5823532 •
  • Format: PDF
Middle East Respiratory Syndrome (MERS) Drug pipeline report- 2020 is an annual R&D review of Middle East Respiratory Syndrome (MERS) pipeline candidates. The report presents the current status of all major Middle East Respiratory Syndrome (MERS) therapeutic compounds. Detailed insights into Middle East Respiratory Syndrome (MERS) pipeline development, current status, companies, drug profiles and Middle East Respiratory Syndrome (MERS) preclinical and clinical trials are included.

2020 Middle East Respiratory Syndrome (MERS) Pipeline Market Insights
Middle East Respiratory Syndrome (MERS) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Middle East Respiratory Syndrome (MERS) therapies, pipeline by phase and others are included.

Middle East Respiratory Syndrome (MERS) pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Middle East Respiratory Syndrome (MERS) Therapeutic Drug candidates
Both active and inactive Middle East Respiratory Syndrome (MERS) pipeline drug candidates are included in the report

Middle East Respiratory Syndrome (MERS) Clinical Trials and preclinical Studies
Middle East Respiratory Syndrome (MERS) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Middle East Respiratory Syndrome (MERS) pipeline market developments
Middle East Respiratory Syndrome (MERS) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Middle East Respiratory Syndrome (MERS) pipeline companies in active development

The report analyzes Middle East Respiratory Syndrome (MERS) pipeline of the below companies-
Autoimmune Technologies LLC, Fabentech, Gilead Sciences Inc, Global BioLife Inc Ltd, Greffex Inc, Humabs BioMed SA, Inovio Pharmaceuticals Inc, Kineta Inc, NanoViricides Inc, Novavax, Inc, Organic Vaccines PLC, Phelix Therapeutics LLC, Planet Biotechnology Inc, Regeneron Pharmaceuticals Inc, Romark Laboratories LC, SAB Biotherapeutics Inc, Signia Therapeutics, Themis Bioscience GmbH, Vaccitech ltd, Vaxine Pty Ltd, Vir Biotechnology Inc

Report Coverage
- What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

- Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

- Companies
21 Companies investing in Middle East Respiratory Syndrome (MERS) pipeline from discovery stage to pre-registration phase are included

- Drug profiles
Over 10 details of each Middle East Respiratory Syndrome (MERS) pipeline candidate are included

- Company Profiles
Business overview and contact details of all companies operating in the industry are provided

- Market Developments
News, Developments and other recent industry developments are included